135,178 AstraZeneca Plc $AZN Shares Acquired by Rathbones Group PLC

AstraZeneca logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Rathbones Group increased its AstraZeneca stake by 135,178 shares, or 1.7%, to 8.11 million shares. The position was valued at about $1.32 billion and represented 4.7% of the fund’s holdings.
  • AstraZeneca beat quarterly earnings and revenue estimates, reporting EPS of $2.79 versus a $2.60 consensus and revenue of $16.21 billion, up 6.5% year over year.
  • Analysts’ consensus rating is Moderate Buy, with a $206.67 average target price; 16 analysts rate the stock Buy and three rate it Hold.
  • MarketBeat previews top five stocks to own in December.

Rathbones Group PLC boosted its position in AstraZeneca Plc (NYSE:AZN - Free Report) by 1.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,114,328 shares of the company's stock after buying an additional 135,178 shares during the quarter. AstraZeneca makes up about 4.7% of Rathbones Group PLC's holdings, making the stock its 4th biggest position. Rathbones Group PLC owned about 0.52% of AstraZeneca worth $1,323,693,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Aries Wealth Management lifted its position in AstraZeneca by 1.3% during the 3rd quarter. Aries Wealth Management now owns 4,546 shares of the company's stock worth $741,000 after acquiring an additional 60 shares during the last quarter. Triumph Capital Management boosted its holdings in AstraZeneca by 32.6% during the third quarter. Triumph Capital Management now owns 252 shares of the company's stock valued at $41,000 after acquiring an additional 62 shares during the period. Claro Advisors Inc. grew its position in shares of AstraZeneca by 5.2% in the third quarter. Claro Advisors Inc. now owns 1,247 shares of the company's stock valued at $201,000 after purchasing an additional 62 shares during the last quarter. Davis Investment Partners LLC grew its position in shares of AstraZeneca by 3.4% in the third quarter. Davis Investment Partners LLC now owns 1,868 shares of the company's stock valued at $302,000 after purchasing an additional 62 shares during the last quarter. Finally, Riversedge Advisors LLC grew its position in shares of AstraZeneca by 2.9% in the third quarter. Riversedge Advisors LLC now owns 2,347 shares of the company's stock valued at $379,000 after purchasing an additional 67 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at $174.20 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79. AstraZeneca Plc has a fifty-two week low of $153.41 and a fifty-two week high of $212.71. The firm has a fifty day moving average price of $170.72 and a two-hundred day moving average price of $180.02. The company has a market cap of $270.17 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24.

AstraZeneca (NYSE:AZN - Get Free Report) last posted its quarterly earnings results on Saturday, October 31st. The company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.60 by $0.19. The company had revenue of $16.21 billion for the quarter, compared to analyst estimates of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The business's quarterly revenue was up 6.5% on a year-over-year basis. During the same period last year, the business posted $2.38 EPS. Analysts expect that AstraZeneca Plc will post 10.22 EPS for the current year.

Wall Street Analyst Weigh In

AZN has been the topic of a number of recent analyst reports. Wall Street Zen upgraded AstraZeneca from a "hold" rating to a "buy" rating in a research note on Saturday, October 31st. Deutsche Bank upgraded AstraZeneca from a "sell" rating to a "hold" rating in a research note on Tuesday, September 15th. Zacks Research raised AstraZeneca from a "strong sell" rating to a "hold" rating in a report on Tuesday, October 13th. Royal Bank Of Canada initiated coverage on AstraZeneca in a research report on Tuesday, September 8th. They issued an "outperform" rating on the stock. Finally, Nordea Equity Research upgraded AstraZeneca from a "sell" rating to a "buy" rating in a report on Tuesday, October 13th. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, AstraZeneca has an average rating of "Moderate Buy" and a consensus target price of $206.67.

Read Our Latest Stock Analysis on AstraZeneca

AstraZeneca Company Profile

(Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN - Free Report).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AstraZeneca Right Now?

Before you consider AstraZeneca, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.

While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines